Quote | ADC Therapeutics SA (NYSE:ADCT)
Last: | $4.97 |
---|---|
Change Percent: | -0.85% |
Open: | $4.72 |
Close: | $4.97 |
High: | $5.08 |
Low: | $4.72 |
Volume: | 401,719 |
Last Trade Date Time: | 04/23/2024 03:00:00 am |
News | ADC Therapeutics SA (NYSE:ADCT)
2024-04-04 13:11:10 ET More on ADC Therapeutics ADC Therapeutics: Real Opportunity With Real Risk In 2024 (Rating Upgrade) ADC Therapeutics SA (ADCT) Q4 2023 Earnings Call Transcript ADC Therapeutics SA 2023 Q4 - Results - Earnings Call Presentation Seeking A...
Dose escalation in Phase 1b trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all patients and early signs of anti-tumor activity Enrollment in Part 2 dose expansion has been i...
Message Board Posts | ADC Therapeutics SA (NYSE:ADCT)
Subject | By | Source | When |
---|---|---|---|
should we be shorting? | 81vette | investorshub | 05/07/2023 8:43:32 PM |
$ADCT bears and bulls | OldAIMGuy | investorshub | 05/07/2023 10:17:45 AM |
$ADCT The trading up | OldAIMGuy | investorshub | 05/07/2023 8:27:53 AM |
$ADCT Thoughts on where this is headed? | ljk | investorshub | 05/02/2023 6:31:39 AM |
MomentumIts gaining | OldAIMGuy | investorshub | 05/01/2023 6:42:33 AM |
News, Short Squeeze, Breakout and More Instantly...
ADC Therapeutics SA Company Name:
ADCT Stock Symbol:
NYSE Market:
Dose escalation in Phase 1b trial completed with no dose-limiting toxicities, no or low-grade cytokine release syndrome and no immune effector cell-associated neurotoxicity syndrome across all patients and early signs of anti-tumor activity Enrollment in Part 2 dose expansion has been i...
LAUSANNE, Switzerland, April 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE:ADCT) today announced that the Company will host a virtual R...
LAUSANNE, Switzerland, April 03, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today announced that the Company will host a virtual Research Investor Event on Tuesday, April 9, 2024, from 4:00 to 5:30 p.m. EDT. The event will feature presentations from Ameet Mallik, Chief Executive Of...